Actinogen Medical
June 17, 2025
Company Presentation
Brain Health
Actinogen is an ASX-listed company conducting late-stage clinical trials in Alzheimer's disease (AD) for its oral small molecule, Xanamem. Xanamem works by controlling the levels of the "stress hormone"cortisol in key areas of the brain associated with AD. Pilot phase 2 data suggests Xanamem can slow AD progression and a recent randomized, phase 2 trial demonstrated anti-depressant activity. A pivotal, phase 2b/3 trial is enrolling in Australia and the US, with interim results due late 2025 and final results in late 2026.
Company HQ City:
Sydney
Company HQ State:
NSW
Company HQ Country:
Australia
Year Founded:
2014
Lead Product in Development:
Oral Xanamem
CEO
Dr Steven G Gourlay, CEO
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
One
Exchange
ASX
Ticker
ACW.AX
When you expect your next catalyst update?
Interim analysis of pivotal Alzheimer's trial late 2025
What is your next catalyst (value inflection) update?
Final results of pivotal Alzheimer's trial late 2026
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}